LNAI vs LTRN

Lunai Bioworks Inc. vs Lantern Pharma Inc. — Valuation Comparison 2026

LNAI

Pharmaceutical Preparations
Lunai Bioworks Inc.
Quality
2.9
out of 10
Value Trap
41
WARN
Price
$3.08
Last close
Models
6/13
Active
VS

LTRN

Pharmaceutical Preparations
Lantern Pharma Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$3.59
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType LNAI Fair ValueLNAI Upside LTRN Fair ValueLTRN Upside
Bayesian DCF Intrinsic $0.06 -97.9% $1.04 -70.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $6.66 +116.1% $0.08 -96.1%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $0.65 -78.8% $3.17 -11.6%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for LNAI vs LTRN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LNAI vs LTRN — Which Stock Is More Undervalued?

LTRN scores higher with a 4.5/10 quality rating vs LNAI's 2.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lunai Bioworks Inc. (LNAI) and Lantern Pharma Inc. (LTRN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LNAI currently trades at $3.08 with a QOC of 2.9/10, while LTRN trades at $3.59 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).